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Vitamin A supplements may interact with diphtheria-tetanus-pertussis (DTP) vaccine causing increased female mortality. In a
randomised trial of neonatal vitamin A supplementation (VAS), we examined growth during the ﬁrst year of life in 808 children,
pursuing the hypothesis that a negative interaction between VAS and DTP in girls would be reﬂected in growth. Length and weight
were measured at 6 weekly visits and WHO-growth-reference z-scores derived. Neonatal VAS had no eﬀect on anthropometric
measures at 12 months, but may interact sex diﬀerentially with routine vaccines. While BCG was the most recent vaccine, neonatal
VAS beneﬁtted growth (diﬀerence in weight-for-length z-score (dWFL: 0.31(95% CI: 0.03–0.59)). While DTP was the most recent
vaccine, VAS tended to aﬀect growth adversely in girls (dWFL = −0.21 (−0.48–0.06)). After measles vaccine (MV) there was no
overall eﬀe c to fn e o n a t a lV A S .T h eV A Se ﬀect diﬀered signiﬁcantly between the BCG and DTP windows (P = 0.03), and the
diﬀerence was borderline signiﬁcant between the DTP and MV windows for girls (P = 0.09).
1.Introduction
VitaminAdeﬁciency(VAD)hasbeenassociatedwithimpair-
ed growth in observational studies [1, 2], but randomised
trials of vitamin A supplementation (VAS) have often failed
to show an impact on growth [3] in spite of improved vita-
min A status in deﬁcient populations [4, 5]. The only study
examining the eﬀect of neonatal VAS on growth reported a
positive eﬀect on height at 3 years of age in Indonesia [6].
Within a randomised placebo-controlled study of the eﬀect
on mortality of providing neonates with 50000IU of vita-
min A with Bacillus Calmette-Guerin vaccine (BCG) [7]w e
examined the eﬀect of neonatal VAS on growth during the
ﬁrst year of life in both sexes.
The present trial as well as a similar trial of neonatal VAS
fromZimbabwe[8]didnotﬁndtheexpectedbeneﬁcialeﬀect
ofVASonmortalityobservedinIndonesia[9]andIndia[10]
and later in Bangladesh [11]. We have previously hypothesis-
edthatVASanddiphtheria-tetanus-pertussis(DTP)vaccines
may interact negatively [12, 13], due to ampliﬁcation of the
negative nonspeciﬁc eﬀects of DTP vaccines.
The nonspeciﬁc eﬀects are the eﬀects of vaccines that
cannot be ascribed to the protection against the targeted
disease(s). For example, observational studies [14, 15]a n d
randomised trials [16, 17] of measles vaccine (MV) indicate
reductions in overall mortality far bigger than the reduction
due to prevention of measles infection. Similarly for BCG,
reductionsinmortalitythatcannotbeascribedtoprevention
of tuberculosis have been seen in randomised [18, 19]a n d
observational studies [20]. The opposite eﬀect is seen after
DTP vaccinations; in areas with herd immunity to pertussis,
DTP has been associated with increased female mortality
reﬂected in increased mortality in DTP vaccinated compared
to unvaccinated children [15] and increased female-male
mortality rate ratio after DTP vaccination [21, 22]. In the
present cohort we found that girls had 2-fold higher morta-
lity after reception of DTP vaccine if they had received VAS
rather than placebo at birth [23]. In the present study, we2 Journal of Tropical Medicine
I II I I I
Birth
BCG
+OPV
BCG
DTP MV
MV
MV
+OPV
DTP
+OPV
DTP
+OPV
6, 10 and 14weeks 9months 1year
BCG window if no DTP
BCG window according to schedule
DTP window according to schedule
DTP window if early MV
DTP window if no MV
BCG vaccine
window:
Vaccine windows according to vaccination schedule of the individual child:
DTP vaccine
window:
Measles vaccine
window:
MV window according to schedule
MV window if early MV
Vaccine windows
according to
recommended
vaccination schedule
DTP
Recommended
vaccination
schedule: End of followup
4.5months
Figure 1: Vaccinations schedule and vaccine windows for infants in Guinea-Bissau.
therefore examined whether VAS administered with BCG at
birth aﬀected growth during the ﬁrst year of life and fur-
thermore whether neonatal VAS interacted with subsequent
routinevaccines.Allanalyseswerestratiﬁedbysexsinceneo-
natal VAS may have sex-diﬀerential eﬀects [7, 9, 24].
2.SubjectsandMethods
2.1. Study Population. Bandim Health Project runs a Health
and Demographic Surveillance System (HDSS) in six subur-
ban districts of the capital of Guinea-Bissau, Bissau. The pre-
sent study was carried out within a neonatal VAS trial which
has been described in detail elsewhere [7]. Brieﬂy, mothers
who gave birth to infants of at least 2500g were invited to
participateinthetrialwhenthechildwasduetobeBCGvac-
cinated at the maternity wards or health centres. A trained
assistant explained the study. Provided maternal consent,
children were randomised to vitamin A or placebo. VAS was
administered orally as 0.5mL of oil containing 50000IU
vitamin A as retinyl palmitate and 10IU vitamin E and
placebo was 0.5mL of oil containing only 10IU vitamin E.
The code was broken when all enrolled children had reached
12 months of age.
2.2. Anthropometrics. The eﬀect on growth was studied in
a subcohort comprising all children aged 0 to 6 weeks of
age when enrolled between July 1, 2004 and November 28,
2004, when the main trial ended. Hence, all children had
beenenrolledintherainyseasonfromJunetoNovember.We
aimed to include 800 children. Children were visited every 6
weeks. Anthropometric measurements were initiated Octo-
ber20,2004.Theoldestofthesechildrenwerethereforemea-
sured for the ﬁrst time at 3 months, corresponding to having
missed one visit by the anthropometry team.
Measurements were made by two trained ﬁeld assistants
who visited the home of the child. The length of the child
was measured supine using a wooden measuring board. The
weight of the undressed child was measured to the nearest
20g using an electronic scale (SECA Model 835). Children,
who were temporarily absent when the house was visited,
were visited later the same or the following day, whereas
children travelling were only visited at the following round.
Children whomovedwithinthestudyareawerelocalizedus-
ing the HDSS and visited at the new address.
2.3. Vaccine Information. The recommended immunisation
schedule in Guinea-Bissau for normal-birth-weight infants
during the conduct of the study was BCG and oral polio
vaccine (OPV) at birth, 3 doses of DTP and OPV at 6, 10,
and 14 weeks, and MV at 9 months of age (Figure 1). The
actual timing of the vaccines varied depending on when the
mother took the child to the health centre for vaccination.
DuetoperiodswithlackofOPV,somechildrenreceivedonly
BCG at birth. This was registered on the inclusion form. The
anthropometry team collected information on vaccination
status of the child when conducting the measurements. Fur-
thermore, vaccination status was assessed through the HDSS
at the home visits every 3 months, and all vaccines admin-
istered at the health centres in the study area are registered
daily. Thevaccinedates collectedbythe anthropometry team
have been validated against these routine data.
Early Measles Vaccine Trial. Some of the children in the pre-
sent VAS at birth trial were later enrolled in an early measles
vaccine trial. Within that trial children, who had received
all three DTP vaccines, were randomised to early MV at 4.5
months of age or no early MV. All children received MV at 9
months of age as recommended [17].Journal of Tropical Medicine 3
Table 1: Baseline characteristics of all children included in the
growth cohort by randomisation group.
Vitamin A Placebo
Number (%) Number (%)
Number 403 405
Sex (Male) 198 (49) 194 (48)
No oral polio vaccine at enrolment 88 (22) 83 (20)
Electricity in the household∗
Yes 142 (35) 140 (35)
No 246 (61) 261 (64)
Bathroom∗
Inside the house 63 (16) 56 (14)
Outside the house 324 (80) 343 (85)
N o n e 0( 0 ) 2( 0 )
Maternal education∗
Any 256 (64) 239 (59)
None 122 (30) 147 (36)
Birth order∗
Primipara 109 (27) 113 (28)
2nd-3rd 156 (39) 142 (35)
4th or higher 124 (31) 147 (36)
Mean (SD) Mean (SD)
Birth weight/kg 3.19 (0.44) 3.23 (0.40)
Weight at incl./kg 3.19 (0.51) 3.22 (0.51)
Weight for age at incl./z-score −0.47 (0.95) −0.38 (0.88)
Length at inclusion 50.2 (2.3) 50.1 (2.3)
Length for age at incl./z-score −0.08 (1.00) −0.12 (0.93)
Maternal age/years 25.0 (5.7) 25.1 (5.6)
Maternal arm circumference/mm 255 (33) 254 (30)
∗Numbers do not add up due to a few with missing information.
2.4. Analytical Strategy and Statistics. We used two comple-
mentary approaches to assess growth patterns in the ﬁrst
year of life. All analyses were conducted by sex as neonatal
VAS may have sex-diﬀerential eﬀects [24, 25]. For the both
approacheswecomparedtheindividualmeasurementstothe
2006WHOgrowthreference[26].Z-scores,thatis,thenum-
ber of standard deviations that a measurement diﬀers from
the reference curve for length for age, weight for age and
weight for length were derived and children were classiﬁed
as stunted (length-for-age z-score < −2) and underweight
(weight-for-age z-score < −2) at all measured time points.
OurﬁrstapproachwastostudywhetherneonatalVASaﬀect-
ed weight for age and length for age at 6 months (when the
childrenwouldbeeligibletoreceiveVASincampaigns;range
4–7 months) and at 12 months (when followup stopped;
range 10–14 months). We compared the z-scores by linear
regression and calculated relative risks of being stunted or
underweight.
In the second approach, we studied the eﬀect of VAS in
the time windows where the BCG, DTP, and MV were the
last vaccines to investigate whether the eﬀect of neonatal VAS
with BCG changed when the immune system was inﬂuenced
sequentially by diﬀerent vaccines (Figure 1). We focused on
changes in weight for length which better catch short-term
changes in growth [27]. The vaccine windows began when
the child received the vaccine in question and ended one
weekaftervaccinationwithadiﬀerentvaccine(oratachosen
cut-oﬀ age if no subsequent vaccine was given). Growth in
the BCG window was deﬁned as the diﬀerence in the weight-
for-lengthz-scorefrominclusiontowithinoneweekafterthe
ﬁrst DTP vaccine (DTP1); if no DTP was given, the last mea-
surement before 4 months of age was used. Similarly, growth
in the DTP window was deﬁned as the diﬀerence in weight-
for-length z-score between the ﬁrst measurement after DTP1
and the last measurement within one week after the ﬁrst MV.
If the child had not received an MV before 12 months of age
the last obtained measurement before/at 12 months of age
was used. Finally, the growth in the MV window was deﬁned
as the diﬀerence in the ﬁrst z-score measured after MV and
the last measurement before/at 12 months of age (Figure 1).
We also conducted the analysis on growth in the MV win-
dow stratiﬁed by reception of early MV at 4.5 months and 9
months of age or routine MV at 9 months.
To contribute in one of the vaccines window analyses a
child should thus have at least two measurements in the time
window. The change in weight for length between the ﬁrst
and the last measurements in a vaccine window was compar-
ed by linear regression. A mixed-eﬀect regression model for
repeated measures was used to examine whether the eﬀect of
VAS diﬀered between the vaccine windows.
OthershavefoundaneﬀectofVASongrowthinvitamin-
A-deﬁcient children [28]. We did not measure vitaminAsta-
tus at the time of supplementation. It has been shown con-
sistently that vitamin A status varies with birth weight, that
is, smaller newborns have poorer vitamin A status [29–
32]. In addition boys have lower cord blood retinol con-
centration [29]. We therefore investigated whether socioeco-
nomic status and weight in the ﬁrst week of life modiﬁed the
eﬀectofVASonweightandlengthforageat6and12months
and on change in weight for length in the vaccine windows.
3. Results
We enrolled 808 children. Of these 490 were later enrolled
in the early measles vaccine trial. At baseline the vitamin
A and placebo groups were comparable (Table 1). Children
included in the growth cohort, but never measured (n = 83),
showed the same distribution of background factors (data
not shown).
We aimed to visit the children approximately every 6
weeks. Mean time between two visits was 46.3 days (standard
deviation (SD) = 9.3). The intervals between two visits did
not diﬀer by randomisation group (P = 0.46). An average of
68% of the children was found at home to be measured at
these visits (VAS: 67%, Placebo: 68%). The majority of those
not measured were travelling at the time of the visit. Of the
808 children included in the growth cohort, 725 (90%) were
measured at least once between inclusion and 12 months of
age. The remaining 83 were not measured for reasons stat-
ed in Figure 2. Twenty-seven children died before 1 year of4 Journal of Tropical Medicine
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Figure 2: Flow of children through the study.
age (19 VAS: 10 boys, 9 girls; 8 placebo: 5 boys, 3 girls), cor-
responding to a relative risk (RR) of loss to followup due to
death for VAS versus placebo of 2.38 (1.06–5.39).
3.1. First Approach: Anthropometric Status at 6 and 12
Months. At 6 months of age there was no overall eﬀect of
VAS at birth on length-for-age z-score (P = 0.58) or weight-
for-age z-score (P = 0.79), and the eﬀect of VAS did not
diﬀer between boys and girls, P = 0.28 for length for age
and P = 0.25 for weight for age. VAS tended to increase the
proportion of stunted girls, but to decrease the proportion
of stunted boys (P for interaction between VAS and sex =
0.11) (Table 2). At 12 months there was no overall eﬀect of
VAS at birth on length for age (P = 0.28) or weight for age
(P = 0.35)(Table 2).Themajorityofthechildrenhadattain-
edalengthbelowthereferencemedian(90%),resultinginan
average length for age of below −1SD in both the VAS and
the placebo groups. VAS tended to beneﬁt the growth in boys
during the ﬁrst year of life but this was not found in girls (P
for interaction between sex and VAS = 0.27 for being stunted
and 0.06 for being underweight).
3.2. Second Approach: Growth by Vaccination Status. In the
timewindowoftheBCGvaccinationtherewasanoverallsig-
niﬁcant beneﬁcial eﬀect of VAS due to a signiﬁcant beneﬁcial
eﬀect for boys (Table 3). In the time window of the DTP
vaccine there was no overall eﬀect of VAS at birth, but a ten-
dency for a negative eﬀect was seen for girls (P = 0.12). In
the time window of the MV there was no eﬀect overall or in
either sex. The overall eﬀect of VAS in the BCG window was
diﬀerent from the eﬀect in the DTP window (P = 0.03), but
did not diﬀer from the eﬀect in the MV window (P = 0.11).
Furthermore, the eﬀect of neonatal VAS tended to diﬀer
between the DTP and MV windows for girls (P = 0.09),
but not for boys (P = 0.67). The beneﬁcial eﬀect in the MV
window may have been slightly stronger among the children
who received an early MV and another one at 9 months of
age. In none of the time windows the eﬀect of neonatal VAS
diﬀered signiﬁcantly between boys and girls (P for inter-
action between VAS and sex = 0.28, 0.18, and 0.61 in the
BCG, DTP and MV windows, resp.).
Due to shortage of vaccine 21% of the children did not
receive OPV at enrolment. The eﬀect of neonatal VAS on
growth at 6 or 12 months of age or in the vaccine windows
did not diﬀer by reception of OPV at enrolment (data not
shown).
3.3. Growth by Markers of Vitamin A Status. Stratiﬁcation by
the background factors presented in Table 1 did not indicate
thattheeﬀectofVASongrowthparametersat6or12months
or in the vaccine windows diﬀered by socioeconomic groups
(data not shown).
In tertiles of weight at enrolment for children enrolled
in the ﬁrst week of life, the eﬀect of VAS was diﬀerent in
boys and girls. VAS tended to have a positive eﬀect in the
lightest girls in the BCG window immediately after supple-
mentation, whereas the eﬀe c tt e n d e dt ob en e g a t i v ei nt h e
heavier girls (P = 0.10 for interaction between VAS and
enrolment weight in the BCG window). In contrast, VAS
tended to have a negative eﬀect in the lightest boys and a
positive in the heavier boys (P = 0.10 for interaction bet-
ween enrolment weight and VAS in boys). This resulted in
a statistically signiﬁcant 3-way interaction between sex, VAS,
and enrolment weight with respect to change in weight for
length in the BCG window (P = 0.01). This eﬀect was not
sustained at 12 months of age (data not shown).
4. Discussion
Children in Guinea-Bissau do not fulﬁl their growth poten-
tial during the ﬁrst year of life according to the WHO refer-
ences. More than half were below minus 1 length-for-ageJournal of Tropical Medicine 5
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z-score at 12 months of age. Overall there was no eﬀect of
neonatal VAS on growth at 6 and 12 months of age, but we
observed a tendency towards a beneﬁcial eﬀect of VAS for
boys but not for girls. The eﬀect of VAS diﬀered by vac-
cination status: VAS was beneﬁcial as long as BCG was the
most recent vaccine. The eﬀect in the BGC window was sig-
niﬁcantly diﬀerent from the eﬀect in the DTP window where
neonatal VAS tended to have a negative eﬀect in girls. The
eﬀect of VAS tended also to diﬀer between the DTP and MV
windows for girls.
4.1. Strengths and Limitations. We measured children enroll-
ed in the randomised trial at home visits, limiting the drop-
out rate and minimising the risk of selection bias associated
with children having to report to a health centre. However,
the frequency of travelling and movements in urban Guinea-
Bissau is high, and only around two-thirds of the children
were measured during each round. For 10% we did not
achieveameasurementatanytimepointduringtheﬁrstyear
of life. However, the baseline characteristics of these child-
ren did not diﬀer from those of the measured children. In
any growth study it could be argued that the results could
be skewed if mortality during followup diﬀered between the
groups. In the present study mortality during followup was
signiﬁcantly higher in the vitamin A than in the placebo
group, in particular among girls. This, if anything, would
tend to mask a negative eﬀect of VAS on growth in girls.
The study of mortality revealed a strong interaction
betweenseasonofsupplementationandVAS,withVASbeing
detrimental for girls in the rainy season, and most benef-
icial for boys in the dry season [7]. Unfortunately, as this
was an unexpected ﬁnding, it was not taken into account
when planning the present study and all enrolments were in
the rainy season Hence, we could study possible eﬀect modi-
ﬁcation by season of enrolment.
4.2. Interpretation. We set out to examine the eﬀect of VAS
with BCG on the growth patterns in the ﬁrst year of life in-
cludingshiftsineﬀectwhentheimmunesystemisinﬂuenced
sequentially by BCG, DTP, and then MV. As expected we
found a positive eﬀect in the BCG window. It seemed most
pronounced for boys. In the time window of DTP, girls had a
tendency for a negative eﬀect of VAS, whereas boys still may
have a slight beneﬁt of being assigned to the VAS group. This
may be due to a nonbeneﬁcial interaction of vitamin A with
DTP in girls, consistent with the mortality results [23]. The
eﬀect of VAS diﬀered signiﬁcantly between the BCG and the
DTP windows, and there was a borderline signiﬁcant diﬀer-
ence between the DTP and MV windows in girls.
It could be argued that that positive eﬀect of VAS in the
BCG window was due to prevention/treatment of VAD, and
this eﬀect waned as vitamin A was consumed. However, this
would not account for the tendency for a negative eﬀect in
the DTP window in girls. Others have found an eﬀect of
VAS on growth limited to groups with low vitamin A status
[33], but this pattern is not supported by our data. In the
present study boys had a more beneﬁcial eﬀect than girls
in the BCG window; however, it was the boys with higher
inclusion weights who seemed to beneﬁt more from VAS
in the BCG window. The opposite was the case for girls.
If the eﬀect is diﬀerent in boys and girls, with a tendency
for most beneﬁcial eﬀect in the least deﬁcient boys and the
most deﬁcient girls immediately after supplementation, it
seems unlikely that the beneﬁcial eﬀect of VAS at birth in
certain subgroups was merely due to a reduction in VAD.
Furthermore, if the eﬀect of VAS on growth depended on
the prevalence of VAD, we would expect a more pronounced
diﬀerence between vitamin A and placebo among those of
lowersocioeconomicstatus[34–36].Wefoundnoindication
that a beneﬁcial eﬀect was seen in subgroups with worse
socioeconomic status. Hence the eﬀect of VAS on growth
may be due to an interaction with the immune system, VAS
aﬀecting susceptibility to infections diﬀerently when BCG
and DTP, respectively, have been administered as the most
recent vaccine.
5. Conclusion
The eﬀect on growth of 50000IU vitamin A given at birth
with BCG vaccine appears to be beneﬁcial for boys, whereas
it tended to be negative for girls who had received DTP. The
mechanisms behind these eﬀects are unknown, but are un-
likely to be explained by prevention of vitamin A deﬁciency.
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